Ilan Danieli

serves as CEO of Precipio, Inc., and is the developer of HemeScreen, a novel proprietary test for mutations in hematologic cancers.
serves as CEO of Precipio, Inc., and is the developer of HemeScreen, a novel proprietary test for mutations in hematologic cancers.

serves as CEO of Precipio, Inc., and is the developer of HemeScreen, a novel proprietary test for mutations in hematologic cancers.

More from Ilan Danieli